Vivek Narayan1, Maneka Puligandla2, Naomi B Haas1, Pearl Subramanian3, Robert S DiPaola4, Robert Uzzo5. 1. Abramson Cancer Center, Philadelphia, Pennsylvania. 2. Dana-Farber Cancer Institute, Boston, Massachusetts. 3. University of Pennsylvania, Philadelphia, Pennsylvania. 4. University of Kentucky, Lexington, Kentucky. 5. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract
PURPOSE: The natural history of nonclear cell renal cell carcinoma following surgery with curative intent remains poorly defined with postoperative surveillance informed by guidelines largely intended for clear cell renal cell carcinoma. We evaluated relapse patterns and potential implications for post-nephrectomy surveillance in patients with nonclear cell renal cell carcinoma enrolled in the E2805 trial, the largest randomized trial of adjuvant antiangiogenic therapy of high risk renal cell carcinoma. MATERIALS AND METHODS: We retrospectively analyzed the records of patients with completely resected nonclear cell renal cell carcinoma. Participants received up to 54 weeks of postoperative therapy with sunitinib, sorafenib or placebo and underwent surveillance imaging at standardized intervals for 10 years. For recurrence rates by site the cumulative incidence was estimated, accounting for competing risks. The adequacy of strict adherence to post-nephrectomy surveillance guidelines was evaluated. RESULTS: A total of 403 patients with nonclear cell renal cell carcinoma were enrolled in the study. During a median followup of 6.2 years 36% of nonclear cell renal cell carcinomas recurred. Five-year recurrence rates were comparable for nonclear and clear cell renal cell carcinoma in the 1,541 patients, including 34.6% (95% CI 29.8-39.4) and 39.5% (95% CI 36.9-42.1), respectively. However, patients with nonclear cell renal cell carcinoma were significantly more likely to have abdominal sites of relapse (5-year recurrence rate 26.4% vs 18.2%, p = 0.0008) and significantly less likely to experience relapse in the chest (5-year recurrence rate 13.7% vs 20.9%, p = 0.0005). Current surveillance guidelines would potentially capture approximately 90% of relapses at any site. CONCLUSIONS: Nonclear cell renal cell carcinoma may show a distinct pattern of relapse compared to clear cell renal cell carcinoma. Our findings emphasize the importance of cross-sectional, long-term imaging in patients with high risk, resected, nonclear cell renal cell carcinoma.
PURPOSE: The natural history of nonclear cell renal cell carcinoma following surgery with curative intent remains poorly defined with postoperative surveillance informed by guidelines largely intended for clear cell renal cell carcinoma. We evaluated relapse patterns and potential implications for post-nephrectomy surveillance in patients with nonclear cell renal cell carcinoma enrolled in the E2805 trial, the largest randomized trial of adjuvant antiangiogenic therapy of high risk renal cell carcinoma. MATERIALS AND METHODS: We retrospectively analyzed the records of patients with completely resected nonclear cell renal cell carcinoma. Participants received up to 54 weeks of postoperative therapy with sunitinib, sorafenib or placebo and underwent surveillance imaging at standardized intervals for 10 years. For recurrence rates by site the cumulative incidence was estimated, accounting for competing risks. The adequacy of strict adherence to post-nephrectomy surveillance guidelines was evaluated. RESULTS: A total of 403 patients with nonclear cell renal cell carcinoma were enrolled in the study. During a median followup of 6.2 years 36% of nonclear cell renal cell carcinomas recurred. Five-year recurrence rates were comparable for nonclear and clear cell renal cell carcinoma in the 1,541 patients, including 34.6% (95% CI 29.8-39.4) and 39.5% (95% CI 36.9-42.1), respectively. However, patients with nonclear cell renal cell carcinoma were significantly more likely to have abdominal sites of relapse (5-year recurrence rate 26.4% vs 18.2%, p = 0.0008) and significantly less likely to experience relapse in the chest (5-year recurrence rate 13.7% vs 20.9%, p = 0.0005). Current surveillance guidelines would potentially capture approximately 90% of relapses at any site. CONCLUSIONS: Nonclear cell renal cell carcinoma may show a distinct pattern of relapse compared to clear cell renal cell carcinoma. Our findings emphasize the importance of cross-sectional, long-term imaging in patients with high risk, resected, nonclear cell renal cell carcinoma.
Authors: Andrew J Armstrong; Susan Halabi; Tim Eisen; Samuel Broderick; Walter M Stadler; Robert J Jones; Jorge A Garcia; Ulka N Vaishampayan; Joel Picus; Robert E Hawkins; John D Hainsworth; Christian K Kollmannsberger; Theodore F Logan; Igor Puzanov; Lisa M Pickering; Christopher W Ryan; Andrew Protheroe; Christine M Lusk; Sadie Oberg; Daniel J George Journal: Lancet Oncol Date: 2016-01-13 Impact factor: 41.316
Authors: Bradley C Leibovich; Christine M Lohse; Paul L Crispen; Stephen A Boorjian; R Houston Thompson; Michael L Blute; John C Cheville Journal: J Urol Date: 2010-02-19 Impact factor: 7.450
Authors: John S Lam; Oleg Shvarts; John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun Journal: J Urol Date: 2005-08 Impact factor: 7.450
Authors: Nizar M Tannir; Eric Jonasch; Laurence Albiges; Emre Altinmakas; Chaan S Ng; Surena F Matin; Xuemei Wang; Wei Qiao; Zita Dubauskas Lim; Pheroze Tamboli; Priya Rao; Kanishka Sircar; Jose A Karam; David F McDermott; Christopher G Wood; Toni K Choueiri Journal: Eur Urol Date: 2015-11-26 Impact factor: 20.096
Authors: Timothy J Williamson; John R Pearson; Joseph Ischia; Damien M Bolton; Nathan Lawrentschuk Journal: BJU Int Date: 2016-01-08 Impact factor: 5.588
Authors: Andrew J Stephenson; Michael P Chetner; Keith Rourke; Martin E Gleave; M Signaevsky; Bruce Palmer; James Kuan; Gerald B Brock; Simon Tanguay Journal: J Urol Date: 2004-07 Impact factor: 7.450
Authors: Peter J Littrup; Hyun J Bang; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lance K Heilbrun; Barbara A Adam Journal: J Vasc Interv Radiol Date: 2013-09-20 Impact factor: 3.464
Authors: Sherri M Donat; Mireya Diaz; Jay Todd Bishoff; Jonathan A Coleman; Philipp Dahm; Ithaar H Derweesh; S Duke Herrell; Susan Hilton; Eric Jonasch; Daniel W Lin; Victor E Reuter; Sam S Chang Journal: J Urol Date: 2013-05-07 Impact factor: 7.450
Authors: Andrew W Silagy; Roy Mano; Kyle A Blum; Renzo G DiNatale; Julian Marcon; Satish K Tickoo; Eduard Reznik; Jonathan A Coleman; Paul Russo; A Ari Hakimi Journal: Urology Date: 2019-11-11 Impact factor: 2.649